0

The Editorial Contents

Hippocrates himself would, today, be surprised at the
astonishing speed with which Medicine has
• Cover Story 2
revolutionized itself. Gone are the days when diseases -- Cancer Drugs Available...
were generalized and treatments meted out were not
specific. We have entered an era where technology has But Unavailable...
the power to pinpoint the cause of diseases at the
genetic level and then can proceed to recommend • Article 4
therapies that would specifically repair these aberrations.
The Human Genome Project has unraveled the -- “Onco”ntrol
mysterious ways in which the genes function and made
way for extensive research related to it.
Cancer is no longer considered a disease linked only to
• ‘Innov’Era 5
environmental factors. Scientists have discovered that -- ‘Can’cer Treatment: A Reality!!!
some forms of the disease like Breast cancer & Ovarian
cancer can occur due to genetic factors as well. Due to
this interdependence, Scientists are looking at therapies
• The Industry Buzz 6
that will work at the genetic level like -- NoMoreSulide
Pharmacogenomics, Gene Therapy, Stem Cell Therapy,
Antisense Therapy, etc. With this emerging new arena in -- Biocon Suffers a Setback as Oral
sight we have thus dedicated this issue of The PUMBA
Gazette to Oncology and its prospective treatments.
Insulin Trials Fail
To broaden our horizons on this topic we personally
interviewed Oncologists in Pune and got their perspective • Candid Talk 7
on the reasons of unavailability of Cancer drugs and what
the pharmaceutical companies are doing to remedy this -- An Interview with Mr. Manish
issue. Pungaliya
Taking the theme further we interviewed Mr. Manish
Pungaliya, Director Ayugen Biosciences in order to
understand the scope of Pharmacogenomics in Cancer • PUMBA News 8
Treatment.
Also included is an article on the current Cancer
-- Dhruv ‘11
treatments that are available to patients. -- Nostalgia 2011
The periodical for this edition elaborates on the host of
alternative cancer therapies that are replacing the -- National Seminar 2011
conventional treatments that were once thought as
irreplaceable.
-- Yukti
The BT news section focuses on the ban on Nimesulide
and phenylpropylamine drugs in India and on the huge
setback to the eagerly awaited oral insulin by Biocon.
We wind up the edition with PUMBA News bringing you
all the happenings that have taken place here in PUMBA.

“Reading maketh a full man; conference a ready

man; and writing an exact man.” - Francis Bacon

Sincerely Yours,
Editor-in-Chief:
Chime Y. Mishra (MBA Biotechnology - SEM IV)
The PUMBA Gazette Team
(The detailed project report shall be provided on enquiry.
Kindly send in your enquiries at
thepumbagazette@gmail.com)

1
 Cover Story
CANCER DRUGS AVAILABLE…
BUT UNAVAILABLE…
The Oncology market has grown at more than double
the rate of global pharmaceuticals, with a CAGR of 8.39%
during 2004–’08. But does the ultimate cause of any drug
development actually being achieved? Even with this
increase in the available drugs as well as reported cases,
are these drugs reaching the final consumer i.e., the
Patient? It is a rarely asked question but an important
one in analyzing the role of pharma companies in
contributing to the oncology treatments. It was the main
objective of this month’s survey by the PUMBA Gazette
team i.e., to assess the availability of cancer drugs to
patients in all terms: drug development, market capture,
cost factor, lack of quick approvals and withdrawals.
The oncologists in the Pune region were interviewed to
gather the information on the availability of drugs, the
reason for this non availability and chiefly the role
pharma companies are playing in making these drugs
available to patients.
AVAILABILITY OF DRUGS
The most incident cancers in Pune were found to be
breast, cervical, oral and lung cancers with the most
recovered one to be breast cancer due to ample drugs
available on the basis of an analysis on the availability of
drugs for certain types of cancer. Drugs are ample for
Lymphoma too. However, the drugs are found to be just
enough for the treatment of lung cancer, prostate cancer,
ovarian cancer, colorectal cancer and leukaemia.
According to oncologists the drugs are scarcely available
for treatment of pancreatic cancer.
REASONS FOR NONAVAILABILITY
Most of the doctors think high drug costs to be the chief
reason for unavailability of the drugs followed by non
development and lack of approvals and trials duration.
There are many indications for which we don’t have any
kinds of drugs yet or if they are being developed the long
duration between the approvals and the commercial
availability is the negating factor as many lives are lost
due to lack of treatment in this duration. Some also find
one of the reasons to be the withdrawal of the drugs
which were found effective for disease curing owing to
the potential side-effects. E.g. Mylotarg of Wyeth which
was approved under the accelerated approval program of
FDA used for the treatment of relapsed acute myeloid
leukaemia (AML). It has been withdrawn owing to lack of
any additional clinical benefit and increased toxicity when
administered with chemotherapy. Another of the main
reasons was also found to be that a few drugs have not
yet been approved in India depriving Indian patients of
the benefits.
COST FACTOR
According to the survey of the PUMBA Gazette team, in
Pune region, almost 70% of the oncologists think that the
drug price being high affects the percentage of patients
recovering from cancer (recovery percentage). The
oncologists have almost 80 % of the patients visiting
them for treatment from lower and middle economic
strata (35% Low, 45% Middle). With this high share of
economically not well-to-do patients with not much of
income to spend in the costly cancer treatment, many
patients die untreated or have to withdraw in the middle,
i.e., less recovery percentage.
A study proves that the newly developed drugs are
costing even higher than the already available drugs.
Some of the newly-approved brands cost USD 150-500K
per life year gained.
“...the addition of ixabepilone to capecitabine
(Xeloda) adds about $31,000 to the overall medical
costs of metastatic breast cancer while providing
about 1 more month of ‘quality-adjusted’ survival”.
Journal of Clinical Oncology, May 1, 2009.
This and many more studies suggest that the drugs’ reach
to the economically backwards is reducing. Ironically,
with the development of newer drugs this class of society
2
is getting even more deprived of treatment due to high
costs.
WHY THE COSTS ARE HIGH?
Almost 50% of doctors directly blame the high costs of
drugs on the pharma companies saying that the motive
behind such high prices is just high profit as they are
ultimately doing a business and they are in business to
add to their bottom line inconsiderate to the fact that
these drugs are necessities which need to reach more
and more people. They also think that the unavailability
of any alternative also adds as an advantage to the
companies’ high profit motive until any competition
comes up. An equal number of respondents do not blame
it on the companies directly but the need to recover the
huge costs companies have put into the research and
development of these drugs as a reason behind the high
prices.
ARE COMPANIES DOING ANYTHING?
A 29% of the oncologists’ perception is that the pharma
companies are just profit oriented and are not playing
any role in the drug reach increase. But a good 71% think
that even being profit oriented some initiatives are being
taken by the companies so as to make the drugs reach
more and more patients. They have rated Pfizer, BMS,
Roche, Cipla and Novartis to be a few companies active in
doing so along with Intas Pharmaceuticals, EliLilly, Dr.
Reddy’s Laboratories and Innova Healthcare. Thirty
percent of oncologists say that the companies are giving
free samples to the patients so as to make it reach the
poor. E.g., Novartis’ Gleevec®/Glivec® have been
provided free to the needy patients in India through the
Glivec International Patient Assistance Program (GIPAP).
Patient friendly company policies, reduced costs and
accelerated approvals are few other initiatives by the
companies. Generics are a very good advantage for the
patients as they are the cheaper substitutes to their
branded counterparts with the similar affectivity. A few
companies are also involved in inducing voluntary price
caps on their drugs like Genentech had a price cap on
Avastin at $55000/ year for households having income
less than $75000/year before its withdrawal. Amgen has
a price cap on Vectibix™ in USA since 2006 at $4000/
dose, approximately 20% less than the other antibody on
the market (BMS’s Erbitux®) for metastatic colorectal
cancer. Another of these initiatives are the Pay-for-
Performance programs, e.g., in Britain, Johnson &
Johnson offered a money-back guarantee if Velcade
failed to reduce tumours by at least 25%. However,
Indians are still waiting for any such price cap initiatives.
. The accelerated drugs approvals have been beneficial
but a few people debate that whether accelerated
approvals are improved access to therapeutic
breakthroughs or early release of unsafe and ineffective
drugs? This question is going to remain as we have
examples on both the facets. Mylotarg was approved in
2000 came out to be ineffective and withdrawn in June
2010 and Cetuximab was approved under accelerated
approval program in March 2004 for the treatment of
patients with metastatic colorectal cancer had till yet
been proved good with a few non fatal side effects only.
There are several Patient advocacy groups also who assist
people in accessing the drugs through expanded access
programs and compassionate use programs which allow
patients to receive investigational drugs earlier than
phase III of the clinical trial process i.e., earlier than the
FDA approval. When patient advocacy groups learned
that Herceptin was showing promise in clinical trials, they
pressured the manufacturer, Genentech, to provide the
drug early to certain patients.
WHAT SHOULD COMPANIES DO?
Many doctors suggest that the companies should focus
more on research and development and the
multinationals should have their research centres in India
as the cost of drug development is found to be lesser in
India. The trials should be on larger scale involving more
and more people. The costing should be caps based done
on the basis of class and economic conditions of patients
being served. The rural market should be targeted as a
majority of population stays there and the facilities
should be provided to them not only getting the
companies reach more and more patients but also a
good-will creation in a larger mass. Many people lack
awareness so awareness programs could be a major
benefit to both the sides. Another way to reduce costs is
through licensing and supply deals across countries and
such collaborations which will finally reduce the costs
pressure on the patients. The parallel drug applications
i.e., a single drug to be applicable to other indications
could also be a good way to increase availability, so
research should be directed in these directions as well.
Compiled By:
Richa Vijayvargiya, Shomali Naranje (MBA-BT SEM IV)
Apoorva Joshi, Ektaa Sharma, Neha Shedge, Gurudeep S.
Dodmani, Vinay Pantulwar (MBA-BT SEM II)
3
 Article
“ONCO”NTROL Cancer vaccines represent an emerging type of biological
Cancer vaccines are medicines that belong to a class of therapy that is still mostly experimental. Many clinical
substances known as biological response modifiers. trials are underway to test vaccines as potential
Biological response modifiers work by stimulating or treatments for a wide variety of cancer types.
restoring the immune system’s ability to fight infections
and diseases. There are two broad types of cancer
vaccines:
* Preventive (or prophylactic) vaccines, which are
intended to prevent cancer from developing in healthy
people.
* Treatment (or therapeutic) vaccines, which are
intended to treat an existing cancer by strengthening the
body’s natural defenses against the cancer.

Active Clinical Trials of Cancer Treatment Vaccines by

In one early-stage study, 18 of 20 patients who were
Type of Cancer:
vaccinated against non-Hodgkin's lymphoma stayed in
 Bladder Cancer
remission for an average of four year. The vaccine used in
 Brain Tumors
this study contained a protein specific to each patient’s
 Breast Cancer
tumor cells (that is, each patient was given an autologous
 Cervical Cancer
vaccine) as well as two other substances to help boost
 Hodgkin Lymphoma
the immune response. A large, randomized, phase III trial
 Kidney Cancer
of this vaccine is now under way.
 Melanoma
 Multiple Myeloma
From the market perspective, there are going to be
 Leukemia
multiple launches of vaccines between 2010 and 2013-
 Lung Cancer
14, which would substantially increase the market size
 Non-Hodgkin Lymphoma
and growth. The cost of three complete dose courses of
 Pancreatic Cancer
the vaccines ranges approximately from $380 to $400.
 Prostate Cancer
The cancer vaccines developmental pipeline is strong
 Solid Tumors
with about 239 products in various phases of clinical
development including 21 molecules in Phase III. The
Active Clinical Trials of Cancer Preventive Vaccines by
Phase III pipeline activity is strong. It mainly consists of
Type of Cancer:
clinical studies involving antigen/adjuvant vaccines
 Cervical Cancer
regimen. The Phase III pipeline also contains some novel
 Solid Tumors
therapeutic vaccines. These options are also present in
Worldwide, there is the potential to prevent 1.8 million
the Phase II stage pipeline. With all these factors, it is
cases of cancer (18%) each year by fighting infections.
likely that the options in the pipeline will cause a
The proportion is even larger in the third world, where an
dramatic change in the market in the near future and the
estimated one in four cancers is linked to infection.
market activity will primarily be dominated by the
The U.S. Food and Drug Administration (FDA) has
molecules in the Phase II and Phase I pipeline.
approved two vaccines, Gardasil® and Cervarix®, that
The questions that need to be answered via research:
protect against infection by the two types of Human
Papilloma Virus—types 16 and 18—that cause  Whether vaccines will be more effective when
approximately 70 percent of all cases of cervical cancer given in combination with other forms of cancer
worldwide. At least 17 other types of HPV are responsible therapy
for the remaining 30 percent of cervical cancer cases.  Whether the vaccine should be administered
HPV types 16 and/or 18 also cause some vaginal, vulvar, before chemotherapy, during chemotherapy or
anal, penile, and oro-pharyngeal cancers. Therefore, after the course is completed.
researchers must develop new vaccines that are able to  For therapeutic vaccines, the question is at which
prevent infections by all HPV types that can cause this stage should the vaccination be given?
disease.  Whether vaccines can be used in case of cancers
in multiple tissues?
In April 2010, the FDA approved the first cancer
treatment vaccine. This vaccine, sipuleucel-T (Provenge®, Compiled by:
manufactured by Dendreon), is approved for use in some Shalet M. Koshy (MBA Biotechnology SEM IV)
men with metastatic prostate cancer. Anjali Joshi (MBA Biotechnology SEM II)

4
 ‘Innov’Era
‘CAN’CER TREATMENT: A REALITY!!! and the general population. This presents a sizeable
market opportunity. Research is being conducted in both
In India, cancer is a silent crisis. It goes largely
ovarian cancer and prostate cancer, which could have
unreported, and elicits little of the attention it deserves
wide-market implications. Specifically, companies are
from health authorities preoccupied with other pressing
looking to validate new biomarkers in order to create
health problems. Efforts at prevention and early
more accurate tests.
detection are extremely limited, as are diagnostic and
treatment services. Cancer survival rates in India are
Apart from commonly used chemotherapy, hormonal
exceptionally poor. Lack of awareness, stigma, and
therapy and radiotherapy, few therapies like stem cell
reliance on traditional healers mean most people do not
transplantation, electromagnetic radiation therapy,
seek medical help in time. Also, there is a common
dendritic cell (antigen presenting cells) based vaccines,
perception that cancer is transmissible, which leads to
antisense therapy etc. have emerged as novel ways to
patients being shunned by family and friends and inhibits
treat cancer. As the name suggests, stem cell
people from accessing screening or acknowledging early
transplantation is transplantation of multipotent
symptoms. More than two third of cancer patients are
hematopoietic stem cells or blood, often derived from
first seen with late stage disease, which has a poor
bone marrow, umbilical cord blood or hemopoietic stem
prognosis and is long, difficult and costly to treat.
cells derived from a placenta into the patient as part of
the therapy.
Despite public policy measures to prevent cancer, such as
tobacco control and vaccination against HPV (Human
In electromagnetic radiotherapy, low power, non-
Papilloma Virus), cancer is sure to remain a significant
ionizing, non thermal, radio or sub-radio frequency
public health problem throughout the 21st century. The
electromagnetic waves are produced which are helpful in
demographic shift towards an ageing population and the
treating the cancer.
usage of high–tech modern medicine throughout the
emerging economies of Asia and Africa will lead to the
A dendritic cell based cancer vaccine induces strong
expansion of the market for cancer diagnostics globally.
anticancer immunity by its potent immune-inducing
abilities. It is a new paradigm in cancer treatment which
Early diagnosis of cancer is essential to determine the
induces not only strong anti-tumour immunity but also
treatment regime. Computerized tomography, positron
immune memory to prevent tumour recurrence or
emission tomography, magnetic resonance imaging and
metastasis. In this vaccine a live attenuated virus is used
ultrasound imaging are some of the techniques used for
which infects both healthy cells and tumour cells but it
cancer detection. However these techniques are
selectively replicates in tumour cells resulting in killing
expensive, require lab facilities and highly trained
tumour cells and leaving healthy cells unaffected. It also
technicians, they are time consuming and cannot be
results in production of antigens which induces tumour
taken into the field. Nanotechnology is one of the recent
specific immune response, resulting in identifying and
technologies used for cancer diagnosis. Nanotechnology
destroying tumour cells systematically.
is in a unique position to produce a new generation of
early cancer detection techniques with higher sensitivity
Antisense therapy has emerged as an exciting and
and delivery of the drug to the target site.
promising strategy for cancer therapy which works at the
genetic level to prevent mutated or overactive genes by
The latest Technologies in Oncology Diagnostics range
directing the synthesis of proteins that are causing
from body imaging and cytology to molecular diagnostics
cancer. They are different
and pharmacogenomics. The imaging techniques involve
from conventional drugs
Magnetic Resonance Imaging (MRI), X-ray, Computed
as these are designed to
Tomography (CT), Ultrasound, Positron Emission
interact with protein
Tomography (PET), Single Photon Emission Computed
molecules after they are
Tomography (SPECT) and Flow Cytometry. Similarly, the
produced. Antisense
molecular diagnostics include Fluorescence In-Situ
drugs have a more
Hybridization (FISH), Polymerase Chain Reaction (PCR),
selective action, and they have the potential to be more
HPV testing, Immunoassays & Biomarkers, Microarrays
effective and less toxic than conventional drugs.
and Comparative Genomic Hybridization (CGH).
Molecular diagnostics and biomarkers are the key drivers
Compiled by:
of the oncology diagnostics market. Virtual colonoscopy,
Hitesh Patil (MBA-BT SEM IV)
using CT scans to build a picture of the colon, is becoming
Neha Shedge & Seema Pawar (MBA-BT SEM II)
an increasingly accepted alternative to invasive
colonoscopy for colorectal screening in high risk groups

5
 The Industry Buzz
NOMORESULIDE…
It seems that the Drug Technical Advisory Board of India
has pulled its socks and rolled its sleeves once again. It
has finally decided to impose ban on the
commercialization two very controversial drugs being
sold in Indian market namely NIMESULIDE and PHENYL
PROPYLAMINE (widely known as PPA). The move comes
after the debate that has lasted for a decade. The debate
was whether to ban Nimesulide in India or not.
The Nimesulide drug has already been banned in the
developed countries like Britain, Canada, Sweden,
Denmark, New Zealand, Japan and many more. In USA
the drug was not even filed for marketing. The main
reason behind the ban imposed on the drug is the severe
liver damage it causes. It was marketed in India despite of
being banned in the developed countries.
Along with Nimesulide, Phenyl Propylamine, Cisapride
are the other two drugs which DTAB has banned in India.
PPA is the drug used in popular brands like D’cold, Vicks
Action 500 often prescribed for cold and cough remedies.
PPA was reported to be the reason of stroke in many
young women. Whereas Cisapride prescribed to increase
the gastric motility in the upper GIT was reported to
cause serious heart related problem such as disturbed
rhythms of heart beats.
The Nimesulide tablet holds the market of Rs. 2710
Crores in Rs. 50000 Indian Pharma Market. According to
the Drug Controller the drug should have been banned in
India before 10 years ago but were not banned.
Previously, two more drugs were banned in India. Those
were Rosiglitazone which is an anti diabetes drug and the
other one is Sibutramine. These were banned in India in
the month of November.
In the defence, the manufacturers and the marketers of
Nimesulide argued that the manufacturers of
Paracetamol and Ibuprofen were trying to get the drug
banned because of the higher revenues it generated and
it had nothing to do with the adverse effects it caused.
However the test results as well as the reports from the
market always pointed that the problems posed are
serious and need attention.
BIOCON SUFFERS A SETBACK AS ORAL
INSULIN TRIALS FAIL...
Biocon suffered a serious setback this month when the
results of the clinical trials on the much awaited oral
insulin drug failed. The clinical trials on the drug failed to
meet the primary goals.
The drug is named as IN-105 by the company and had
cleared the Phase II of the clinical trials. The drug in
clinical trials has to prove the efficacy test to reach the
very important phase III. In the human clinical trials of IN-
105, it was supposed to lower the level of glycated
haemoglobin by 0.7% however it failed to lower the
levels as compared to placebo.
In this case the effects on placebo were higher than
expected by the researchers. The company said that they
had not considered certain facts about the placebo and
the assumptions proved to be wrong. However the
company claims to have collected enough data to show
that the results are positive and the research is on right
track.
The Biotech giant now has extended its arms to the
global partnerships for the further research on the
molecule. The company plans to enter into global
partnerships and thus conduct more research and more
clinical trials. The company is highly optimistic about the
output of the research studies and the clinical trial
report.
This drug and molecule being one of the most promising
and the emerging market has given a lot of hopes to the
company as well as the Indian Biotechnology. It will be
interesting to see how the molecule, on which Biocon has
been researching since around 2001, fares in coming
days.
Compiled by:
Sumantsinh Girase (MBA Biotechnology SEM IV)
6
 Candid Talk
AN INTERVIEW WITH MR. MANISH
PUNGALIYA
Pharmacogenomics can
be described as the study
of the effects of genetic
variation on the efficacy
and toxicity of a particular
drug. Today oncology and pharmacogenomics is a hot
topic in the current diagnostics market. In order to
understand this association, the interview team spoke
with Mr. Manish Pungaliya, Director, Ayugen
Biosciences. Ayugen is one of the few companies
currently working in the field of pharmacogenomics
testing.
Q.1. “Pharmacogenomics, a powerful tool to enhance
cancer treatment”. What are your views on this
statement?
Pharmcogenomics is drawing attention towards itself in
oncology because most of the new drugs to treat it are
based on targeted therapies i.e. they target a particular
pathway or a gene in a pathway or a protein. Therefore,
most of these drugs will only work based on a particular
genetic profile of the tumour. Pharmacogenomics can
guide practitioners through its genetic profiling tests as
well as about which medication will work in a patient and
which won’t work.
Q.2. Even though pharmacogenomics plays a vital role in
cancer treatment, do you think it is being utilised
efficiently in India as compared to western countries? If
not so, what do you think are the probable reasons for
its underutilisation?
Pharmacogenomics is not being utilized to its full
potential in our country because most of the doctors
don’t know about the tests and their usage. They are not
aware about the benefits and the power of these tests
and even if the doctors are aware of the test they don’t
know how to apply them. But the bright side is that more
and more pharmaceutical companies are pushing the use
of these tests with their drugs, thus the awareness and
usage will increase rapidly in the future. There is also a
cost factor involved in the successful application of this
technique and currently it’s a barrier to the acceptance of
this form of therapy.
Q.3. What steps can be taken to get Pharmacogenomics
Diagnostics for cancer treatment within the reach of the
common man?
In the future the cost of the test will automatically come
down as the volume of patients increase, which is bound
to happen, considering the utility of these tests. Apart
from this best way to get the costs down would be to tie
up with government organizations that can help bring
these tests to the common man at subsidized rates.
Q.4. What is the current share of pharmacogenomics in
the Indian diagnostic industry? And what is your
forecast for the next 5 years for this industry?
The current share of pharmacogenomics in the
diagnostics industry is somewhere around 5-6 %.
However, this scenario will definitely change in the future
as the growth potential is tremendous and the Indian
molecular diagnostics market is expected to cross US$ 3
billion by 2015. In keeping with the proportion of the
pharmacagenomics market share, there will be an
exceptional growth in this sector too.
Q.5. What are the current as well as the untapped
opportunities in cancer pharmacogenomics?
There is a host of other tests that are available that can
be developed to check the side effects and efficacy of a
drug in a patient’s body based on drug metabolism and
site of action. Also there are other genomics tests which
try and understand the gene and protein expression in
the patient’s body once the drug has been administered.
Q.6. What factors should a new entrant take into
account before stepping into this field?
A new entrant must keep in mind that they should be
ready with a full fledged marketing plan and a proper
implementation plan to create awareness among the
practitioners. Another factor for consideration is to try
and bring the cost down from the current levels. The
major aspect to be worked upon is the awareness levels
in the market since it’s a new field in India. Initially the
investment would be high but the returns on investment
will certainly follow. Therefore any new entrant must
have enough patience to fuel this industry.
Compiled by: The PUMBA Gazette Interview Team
7
 The PUMBA News
DHRUV ‘11
DHRUV ’11, one of the most awaited cultural events was
held from 17th -19thJan 2011. This year the theme for
DHRUV was “AQUATICA.” This event gives the students,
from leading B-Schools, an opportunity to present their
managerial, cultural & sports skills to come out and
perform in front of all & compete with others. More than
5000 participants registered their names for various
events. The Grand Finale was held on 19th Jan 2011 at
‘Alpabachat Bhavan’ which comprised of the finals for
‘dance competition’ and ‘fashion show’. The chief guest
for the Grand Finale was Mr. Nandkishor Kapote, the
renowed Kathak dancer and disciple of Pandit Birju
Maharaj. The judges for the evening were Abhilasha
Mahant Choudhary, Director ‘Nach India’ and Vikram ,
Choreographer from Jhalak Dikhla Ja.’ The event
concluded with overall prize distribution and tallying of
points won in various competitions. The General
Championship rolling Trophy is given on the basis of
collective ranking in each individual event of DHRUV. For
the third consecutive year the trophy for DHRUV’11 was
won by Indira Institute Of Management, Pune.
NOSTALGIA 2011
Nostalgia`11, An Odyssey to Remember is an annual
Alumni meet & was held on 22nd January, 2011 at the
PUMBA campus. This event is a casual gathering of
alumni & is meant for recapturing the past memories of
PUMBA. It’s an attempt to strengthen the relation
between PUMBA and its alumni. This year the event
revolved around the theme of ‘Journey’. Deviating from
the usual on-stage program, the PUMBA campus was
converted into a fete with various games organized by
the students. These were enjoyed by the alumni and the
fun atmosphere pepped up the interactions.
The Event was inaugurated by Dr. Capt. C.M. Chitale,
Professor and Head of Department, PUMBA. The alumni,
who have helped PUMBA in the past year, were
honoured as Star Alumni. Also, PUMBA Art Exhibition,
wherein the paintings, sketches and photographs by the
students were displayed, was appreciated. Prof.
Aniruddha Joshi along with Abhimanyu Tadwalkar of
MBA BT 2nd year & Bhushan Astulkar MBA- BT 1st year,
were adjudged as the best artists through a poll
conducted during the event. Thus, another event was
successfully organized by Alumni cell, the heart of
PUMBA.
NATIONAL SEMINAR 2011
National seminar 2011, a National level seminar, was
held on 29th January, 2011 at Le Meridian, Pune. This
year, the topic of discussion was ‘India on the horizon –
The dawn of a global era’. Dr. Santosh Bhave, Vice
President - HR, Bharat Forge Ltd. graced the event as the
Chief guest and Dr. R.K. Shevgaonkar, Hon. Vice
Chancellor, UoP, as the Guest of Honour along with Dr.
(Capt.) C.M. Chitale, the Head of Department of
Management Sciences (PUMBA). The curtain raiser
movie, based on the theme, was an apt introduction of
the current Indian scenario. There were three panel
discussions in the seminar with the topics being India’s
Global Footprint - How far have we reached?,
Infrastructure Jeopardized- Why can’t we walk the talk?
and Globalization and National Commitment-Can they
go hand in hand?. The panelists included Mr. Rajesh
Ghonasgi, CFO, Persistent Systems Ltd., Mr. Diniar
Patel, Editor-Supplement, Times Of India, Mr.
Unnikrishnan Menon, AGM - Exports, IPCA Labs, Dr. P C
Nambiar, Director - EXIM, Serum Institute of India, Mr. P
Srinivasan, Global Business Head, Chemical Division,
Thermax Ltd., and members of Faculty of PUMBA. The
seminar was concluded with a valedictory speech by Dr.
Ashok Joshi, Dean, Faculty of Management, University of
Pune. With this seminar, the Seminar cell has indeed
added another feather in its cap!
YUKTI
“Yukti” a business plan competition was organized by the
ED Cell at PUMBA campus on 25th January, 2011. The
event consisted of two segments. In the first segment,
“BIZZolution”, candidates were given 100 seconds to
present their business ideas. The second segment,
“BIZZplanmania”, only shortlisted candidates presented
their complete business plan. Students from leading B –
Schools like JBIMS, N.L. Dalmia, K.J. Somaiya, MIT,
Sinhgad Institute participated in these events. Reputed
Industrial personalities were invited to judge the business
plan competition. Vishwas Kale (Vijayesh Industries) and
K.J. Bhumkar (Ex-CMD, Bank of Maharashtra) were the
esteemed judges.
Compiled by: Nazaneen Saify (MBA BT Sem IV)
Mehraj Deshmukh and Nikhil Bhalerao (MBA BT Sem II)